India’s reputation as the “Pharmacy of the World” rests on its ability to produce high-quality generic medicines at affordable prices. However, the past few years have exposed serious quality challenges — from contaminated cough syrups linked to child deaths overseas to chronic non-compliance with Good Manufacturing Practices (GMP) among small-scale manufacturers. In response, India’s drug regulator, the Central Drugs Standard Control Organization (CDSCO), has launched one of its most ambitious quality assurance overhauls in history. This article explains the key reforms — Schedule M (revised GMP), the SHRESTH index, outsourced audits, and the Jan Aushadhi movement — and what international buyers need to know about verifying Indian generic medicine quality in 2026.
🔬 Schedule M (Revised GMP): The Biggest Quality Push in a Decade
In June 2024, the Indian government notified the revised Schedule M under the Drugs and Cosmetics Rules, 1945, introducing WHO-GMP standards as a mandatory requirement for all pharmaceutical manufacturers. The deadline for compliance was set for January 1, 2026 — but the industry’s readiness has been highly uneven (as reported by Business Standard, The Economic Times, and Medical Dialogues, June 2026).
Key requirements of revised Schedule M include:
- Pharmaceutical Quality System (PQS): Manufacturers must implement a comprehensive quality management system aligned with WHO-GMP principles
- Risk management: Formalized risk assessment processes for manufacturing, storage, and distribution
- Equipment validation: Mandatory qualification and calibration of all production equipment
- Stability testing: Rigorous shelf-life studies under controlled environmental conditions
- Water system validation: Pharmaceutical-grade water systems must be validated for purity
- Cleanroom classification: Sterile manufacturing must meet international cleanroom standards (Grade A/B/C/D)
- Documentation overhaul: Electronic batch records and comprehensive audit trails required
- Third-party quality testing: Independent lab verification for critical quality parameters
According to industry reports, fewer than 60% of pharmaceutical MSMEs are fully GMP-compliant as of mid-2026. In Himachal Pradesh, a major pharma manufacturing hub, only 11% of units met the new standards (Medical Dialogues, June 2026). The government has indicated it is unlikely to grant a blanket extension, though some state-level discussions about phased compliance timelines for small manufacturers are ongoing (Business Standard, June 2026).
🏭 CDSCO Outsourced Audits and the 1,500-Expert Scientific Cadre
To address its chronic shortage of qualified inspectors, the CDSCO has announced a landmark initiative: outsourcing GMP audits to Quality Council of India (QCI)-certified notified bodies and building a scientific cadre of 1,500 subject matter experts (as reported by ETPharma, Business Standard, and IndiaMedToday, June 2026). This represents a fundamental shift in how India approaches pharmaceutical quality oversight.
What This Means for Quality Assurance
- Third-party audits: QCI-certified bodies will conduct GMP inspections, reducing the inspection backlog and bringing private-sector rigor to regulatory oversight
- Expert cadre: 1,500 specialists across pharmacology, microbiology, chemistry, engineering, and quality systems will process complex product reviews and biologics applications
- Faster approvals: The prior intimation system (introduced January 2026) allows manufacturers to initiate certain changes and clinical trials without waiting for prior CDSCO approval, reducing regulatory bottlenecks
- Targeted enforcement: Risk-based inspection scheduling — high-risk facilities face more frequent audits while compliant units operate with lighter oversight
This outsourcing model mirrors approaches used by the European Medicines Agency (EMA) and the US FDA, where private-sector experts supplement government inspection teams. For international buyers, this means more thorough and consistent quality verification of Indian manufacturing facilities.
📊 The SHRESTH Index: Benchmarking State Drug Regulators
In June 2026, the Union Health Ministry launched the SHRESTH (State Health Regulatory Excellence Index) — a first-of-its-kind national benchmarking framework for state drug regulatory authorities (as reported by PIB, ETPharma, and Pharmabiz.com, June 2026). This index measures state-level regulators across multiple performance dimensions:
- Regulatory efficiency: Timelines for manufacturing license approvals and renewals
- Inspection coverage: Percentage of registered facilities inspected annually
- Quality testing capability: State drug testing lab capacity and accreditation status
- Enforcement actions: Number of notices, suspensions, and prosecutions for non-compliance
- Consumer grievance redressal: Mechanisms for handling quality complaints
- Training and capacity building: Inspector training programs and knowledge management
For international buyers, the SHRESTH index provides a valuable transparency tool. States with higher SHRESTH scores — such as Gujarat, Maharashtra, and Telangana — are more likely to have well-regulated manufacturing units with consistent GMP enforcement. This data can help buyers assess the regulatory environment in different manufacturing regions within India.
🛡️ How to Verify Indian Generic Medicine Quality: A Practical Checklist for 2026
For international buyers and distributors, verifying quality is the most critical step before purchasing Indian generic medicines. Here is a practical checklist aligned with India’s 2026 regulatory framework:
1. Check Manufacturer Licensing and Certification
- Request the manufacturer’s WHO-GMP certificate issued by the state drug regulatory authority (post-Schedule M compliance)
- Verify the certificate through the state drug control department’s public portal
- Check for ISO 9001:2015 or ISO 15378 (primary packaging for pharmaceuticals) certification as supplementary quality indicators
2. Review Regulatory Approval Status
- Confirm the product has CDSCO marketing authorization (drug license number printed on packaging)
- Check if the manufacturer holds US FDA DMF (Drug Master File) or EU CEP (Certificate of Suitability) — an indicator of global regulatory compliance
- Verify the manufacturing site is listed in the WHO prequalification database for the relevant product category
3. Request Batch-Level Quality Documentation
- Certificate of Analysis (CoA) for each batch, covering identity, purity, potency, dissolution, and microbial limits
- Stability data (ICH Q1A-compliant accelerated and long-term studies)
- Bioequivalence study reports (for generic versions of branded drugs — critical for establishing therapeutic equivalence)
4. Conduct Independent Quality Checks
- Have a pre-shipment sample tested by an independent NABL-accredited lab
- Arrange supplier facility audits — either in person or through a qualified third-party inspection agency
- Check for CDSCO recall and quality alert notices related to the manufacturer or product
5. Beware of Warning Signs
- Unusually low pricing (significantly below market average for the same API and dosage form)
- Unwillingness to share batch documentation or provide CoA
- Manufacturer located in a state with low SHRESTH index scores
- Recent FDA warning letters or import alerts against the manufacturer
- No physical site visit or virtual tour offered
💊 The Jan Aushadhi Model: Quality Assurance in India’s Public Generic Drug Program
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — also known as the Jan Aushadhi program — has emerged as a major force in India’s generic medicine landscape. As of early 2026, 17,990 Jan Aushadhi Kendras (outlets) were operational across India, with a target of 25,000 by 2027 (as reported by eHealth Magazine and NDTV, March 2026).
The program sells unbranded generic medicines at prices up to 80% lower than branded equivalents. A 2026 study published by The New Indian Express confirmed that generic medicines are as effective as branded ones priced up to 14 times higher. Quality is maintained through:
- Manufacturers selected through a rigorous tender process requiring WHO-GMP compliance
- Random batch testing at NABL-accredited labs before distribution
- Centralized procurement through the Bureau of Pharma PSUs of India (BPPI)
- Stringent product substitution policies — only bioequivalent generics are allowed
The Jan Aushadhi model demonstrates that India has the systems and infrastructure to produce quality generic medicines at scale. The key for international buyers is to access the same quality assurance channels that the domestic program uses, rather than relying on brokers or unverified intermediaries.
🌐 What International Buyers Need to Know in 2026
The year 2026 marks a turning point for Indian pharmaceutical quality assurance. The regulatory infrastructure is being fundamentally rebuilt — from revised GMP standards and outsourced audits to transparent state-level benchmarking. However, the transition is still incomplete, and quality outcomes remain variable across manufacturers.
Key takeaways for buyers:
- Due diligence is non-negotiable: Schedule M compliance is a minimum threshold, not a guarantee — always verify individual manufacturer credentials
- Large manufacturers lead quality: Top Indian companies (Sun Pharma, Dr. Reddy’s, Cipla, Zydus, Lupin, Aurobindo) already operate at global GMP standards and are well-positioned for Schedule M compliance
- Small and mid-size manufacturers vary: Some are rapidly upgrading facilities to meet the January 2027 deadline; others may face closure. Verify each supplier’s GMP status individually
- Regulatory transparency is improving: The CDSCO outsourced audit model and SHRESTH index create new data sources for assessing manufacturer reliability
- Third-party labs offer a safety net: NABL-accredited testing services are widely available and affordable for pre-purchase quality verification
For a list of verified and reliable pharmaceutical distributors who can connect international buyers with quality-assured Indian generic medicines, refer to the IMSDA’s verified member directory. This resource helps buyers identify trustworthy partners who operate within India’s regulatory framework and maintain strict quality standards.
✅ Conclusion
India’s generic drug quality landscape in 2026 is undergoing its most significant transformation in decades. The revised Schedule M requirements are pushing thousands of manufacturers to upgrade their facilities to WHO-GMP standards. The CDSCO’s outsourced audit initiative and 1,500-expert cadre deployment are dramatically expanding regulatory capacity. The SHRESTH index brings unprecedented transparency to state-level enforcement. And the Jan Aushadhi program proves that India can deliver quality generics at scale.
For international buyers, the window for easy sourcing of substandard products is closing. The regulatory direction is clear: only GMP-compliant, independently verified manufacturers will continue to operate. Buyers who invest in proper due diligence — checking WHO-GMP certification, requesting CoA and bioequivalence data, and engaging with verified distributors — will find India’s generic medicine market more reliable and transparent than ever before.
For more information, contact IMSDA at contact@indiamedicine.org.